{"disease":{"id":"hemophilia","name":"hemophilia"},"drugs":{"marketed":[{"drug_id":"fitusiran","indication_name":"Hemophilia A","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qfitlia","generic_name":"FITUSIRAN","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Antithrombin-directed RNA Interaction [EPC]","quality_score":10,"revenue":"400","mechanism":"Qfitlia works by using small RNA molecules to block the production of antithrombin, a protein that can interfere with blood clotting."},{"drug_id":"fitusiran","indication_name":"Hemophilia B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qfitlia","generic_name":"FITUSIRAN","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Antithrombin-directed RNA Interaction [EPC]","quality_score":10,"revenue":"400","mechanism":"Qfitlia works by using small RNA molecules to block the production of antithrombin, a protein that can interfere with blood clotting."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"cyklokapron","indication_name":"Reduce or prevent hemorrhage in hemophilia patients during tooth extraction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyklokapron","generic_name":"Tranexamic Acid","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Plasminogen lysine binding sites; fibrin","drug_class":"Antifibrinolytic agent","quality_score":60,"revenue":null,"mechanism":"Tranexamic acid occupies lysine receptor binding sites on plasmin, preventing fibrin dissolution."},{"drug_id":"cyklokapron","indication_name":"Reduce or prevent hemorrhage in hemophilia patients following tooth extraction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyklokapron","generic_name":"Tranexamic Acid","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Plasminogen lysine binding sites; fibrin","drug_class":"Antifibrinolytic agent","quality_score":60,"revenue":null,"mechanism":"Tranexamic acid occupies lysine receptor binding sites on plasmin, preventing fibrin dissolution."},{"drug_id":"cyklokapron","indication_name":"Reduce need for replacement therapy in hemophilia patients during tooth extraction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyklokapron","generic_name":"Tranexamic Acid","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Plasminogen lysine binding sites; fibrin","drug_class":"Antifibrinolytic agent","quality_score":60,"revenue":null,"mechanism":"Tranexamic acid occupies lysine receptor binding sites on plasmin, preventing fibrin dissolution."},{"drug_id":"cyklokapron","indication_name":"Reduce need for replacement therapy in hemophilia patients following tooth extraction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyklokapron","generic_name":"Tranexamic Acid","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Plasminogen lysine binding sites; fibrin","drug_class":"Antifibrinolytic agent","quality_score":60,"revenue":null,"mechanism":"Tranexamic acid occupies lysine receptor binding sites on plasmin, preventing fibrin dissolution."},{"drug_id":"gbt021601","indication_name":"Treatment of adult patients with severe hemophilia A with inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gbt021601","generic_name":"gbt021601","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"pf-07202954-single-dose","indication_name":"Hemophilia A","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07202954 Single Dose","generic_name":"pf-07202954-single-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07202954-single-dose","indication_name":"Hemophilia A with inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07202954 Single Dose","generic_name":"pf-07202954-single-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl3990039","indication_name":"hemophilia A (congenital factor VIII deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"MARSTACIMAB","company_name":"Pfizer Inc","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":"Hympavzi works by binding to Factor Xa, a protein involved in blood clotting."},{"drug_id":"chembl-chembl3990039","indication_name":"hemophilia B (congenital factor IX deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"MARSTACIMAB","company_name":"Pfizer Inc","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":"Hympavzi works by binding to Factor Xa, a protein involved in blood clotting."},{"drug_id":"chembl-chembl3990039","indication_name":"hemophilia A (congenital factor VIII deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"MARSTACIMAB","company_name":"Pfizer Inc","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":"Hympavzi works by binding to Factor Xa, a protein involved in blood clotting."},{"drug_id":"chembl-chembl3990039","indication_name":"hemophilia B (congenital factor IX deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"MARSTACIMAB","company_name":"Pfizer Inc","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":"Hympavzi works by binding to Factor Xa, a protein involved in blood clotting."},{"drug_id":"tranexamic-acid","indication_name":"Hemorrhaging in Hemophilia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyklokapron","generic_name":"TRANEXAMIC ACID","company_name":"Exela Pharma","drug_phase":"marketed","molecular_target":"Plasminogen","drug_class":"Antifibrinolytic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Tranexamic acid works by binding to plasminogen and preventing its conversion to plasmin, thereby inhibiting fibrinolysis."},{"drug_id":"xyntha","indication_name":"Hemophilia A","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xyntha","generic_name":"xyntha","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Coagulation factor VIII","drug_class":"Recombinant protein therapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"concizumab","indication_name":"hemophilia A (congenital factor VIII deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"concizumab","indication_name":"hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"concizumab","indication_name":"hemophilia B (congenital factor IX deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"concizumab","indication_name":"hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"amchafibrin","indication_name":"Hemorrhaging in Hemophilia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amchafibrin","company_name":"Fundación Pública Andaluza Progreso y Salud","drug_phase":"phase_3","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"transamin","indication_name":"Hemorrhaging in Hemophilia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"transamin","company_name":"Erzincan Military Hospital","drug_phase":"phase_3","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"marstacimab","indication_name":"Hemophilia A or B","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Marstacimab","generic_name":"marstacimab","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"For patients aged 12 years or older and weighing at least 35 kg, marstacimab is administered subcuta","quality_score":0,"revenue":null,"mechanism":"Marstacimab blocks a protein that normally prevents blood clotting, allowing patients with hemophilia to form clots more easily."},{"drug_id":"nonacog-alfa-genetical-recombination","indication_name":"Hemophilia B","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nonacog Alfa (Genetical Recombination)","generic_name":"nonacog-alfa-genetical-recombination","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered ","quality_score":null,"revenue":null,"mechanism":"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered "}],"offLabel":[],"totalMarketed":23,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT06820515","title":"ATHNdataset Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200000,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT04883710","title":"The World Federation of Hemophilia Gene Therapy Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"World Federation of Hemophilia","has_results":false},{"nct_id":"NCT06727669","title":"Longitudinal Cohort of Thrombosis and Hemostasis Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03596814","title":"MOTHIF II : THERAPEUTIC MANAGEMENT AND USE OF CLOTTING FACTORS IN HEMOPHILIA A & B IN FRANCE II","phase":"","overall_status":"COMPLETED","enrollment_count":2072,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04390126","title":"COVID-19 Related Lockdown Effects On Chronic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":1343,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT00344435","title":"Genetic Susceptibility to Factor VIII Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":1187,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT03533504","title":"Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT03549858","title":"Patient Reported Outcomes Burdens and Experiences - Phase 3","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT02078427","title":"ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)","phase":"","overall_status":"COMPLETED","enrollment_count":951,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT05217992","title":"Are There Differences Between Carriers of Haemophilia A and B?","phase":"","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","has_results":false},{"nct_id":"NCT05628558","title":"Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Groupe Maladies hémorragiques de Bretagne","has_results":false},{"nct_id":"NCT02912143","title":"German Pediatric Hemophilia Research Database","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Goethe University","has_results":false},{"nct_id":"NCT03615053","title":"Personalized Medicine for Canadians With Hemophilia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT06008938","title":"An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT07454239","title":"EPOCH-Economics and Patient Outcomes in China in Haemophilia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06938542","title":"Palliative Care Needs of Children With Rare Diseases and Their Families","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":480,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT06158334","title":"Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03619863","title":"ATHN 7: Hemophilia Natural History Study","phase":"","overall_status":"COMPLETED","enrollment_count":395,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT03932201","title":"Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":371,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05449197","title":"Evaluation of the Training Program for Community Pharmacists for Dispensing Emicizumab (HEMLIBRA®) in France","phase":"","overall_status":"COMPLETED","enrollment_count":363,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06020456","title":"Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A","phase":"","overall_status":"COMPLETED","enrollment_count":361,"lead_sponsor_name":"Groupe Maladies hémorragiques de Bretagne","has_results":false},{"nct_id":"NCT07416604","title":"A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03824522","title":"Post Marketing Surveillance Study for ADYNOVATE in South Korea","phase":"","overall_status":"COMPLETED","enrollment_count":341,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00340548","title":"Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)","phase":"","overall_status":"TERMINATED","enrollment_count":333,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05580692","title":"A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)","phase":"NA","overall_status":"TERMINATED","enrollment_count":321,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":false},{"nct_id":"NCT01154231","title":"BeneFIX Drug Use Results Survey [All-Case Surveillance]","phase":"","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02830477","title":"Study Evaluating \"Real World\" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis","phase":"","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03623295","title":"The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B","phase":"","overall_status":"COMPLETED","enrollment_count":304,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT06879392","title":"Examination of Physiotherapists' Knowledge, Awareness and Competence on Physical Activity and Exercise in Hemophilia Patients","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Gulhane School of Medicine","has_results":false},{"nct_id":"NCT03754790","title":"Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":281,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT02396862","title":"Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04644575","title":"Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":261,"lead_sponsor_name":"Bioverativ, a Sanofi company","has_results":false},{"nct_id":"NCT03157154","title":"Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies","phase":"","overall_status":"COMPLETED","enrollment_count":259,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03834727","title":"Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"Oregon Health and Science University","has_results":false},{"nct_id":"NCT02172950","title":"An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":246,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT05145127","title":"Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":245,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03185897","title":"Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia","phase":"","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT03947567","title":"Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT03818529","title":"ATHN 8: Previously Untreated Patients (PUPs) Matter Study","phase":"","overall_status":"COMPLETED","enrollment_count":237,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT02941783","title":"Drug Use Investigation of Kovaltry in Hemophilia A Patients","phase":"","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02476942","title":"A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01945593","title":"BAX 855 Continuation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT03587116","title":"A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":212,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04158934","title":"A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":207,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT07101224","title":"Data Registry in Chinese Hemophilia A and B Patients","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05911763","title":"A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Sanofi","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}